[D2-A1-02]Establishing Appropriate Immunogenicity Assay Cut Points in Oncology Disease Indications
*Michael A Partridge1(1. Regeneron Pharmaceuticals Inc)
Password required to view
Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.
Password is required to view the abstract. Please enter a password to authenticate.
